Abstract

BackgroundThe indication for hepatic resection (HR) in patients suffering from liver metastases (LM) other than colorectal and neuroendocrine tumors is one focus of current multidisciplinary, oncologic considerations. This study retrospectively analyzes outcome after HR for non-colorectal, non-neuroendocrine (NCNNE) LM in the absence of distant or extrahepatic metastases.MethodsWe included 100 consecutive patients undergoing HR for isolated NCNNE LM from a prospective database in our institution, including postoperative follow-up. Primary tumors were of mesodermal origin in 44%, of ectodermal origin in 29% and of entodermal origin in 27%. Survival analysis was performed by univariate and multivariable methods. Mean follow-up after hepatic surgery was 3.6 years (0.25–16).ResultsMedian age at the time of HR was 59.5 years. Kaplan-Meier-estimated survival after liver resection was 56.8%, 34.3% and 24.5% after 5, 10 and 15 years, respectively. Univariate analysis after HR revealed residual disease (hepatic or primary; p = 0.02), female gender (p = 0.013), entodermal origin (p = 0.009) and early onset of metastatic disease (≤24 months, p = 0.002), as negative prognostic factors. Multivariable survival analysis confirmed residual disease, female gender, entodermal embryologic origin and early onset of metastatic disease (≤24 months) as independent negative prognostic factors.ConclusionOverall outcome after HR of NCNNE LM results in acceptable long-term outcome. Although individual decision-making today mostly relies on clinical experience for this type of disease, risk factors derived from the embryologic origin of the tumor might help in patient selection.

Highlights

  • The indication for hepatic resection (HR) in patients suffering from liver metastases (LM) other than colorectal and neuroendocrine tumors is one focus of current multidisciplinary, oncologic considerations

  • Current evidence shows a benefit for resection of hepatic metastases in Colorectal carcinoma (CRC) independent of number or size, as long as complete tumor clearance can be accomplished [4]

  • Adam et al have published a paramount multicenter series in 2006, including 1452 patients with NCNNE from 1983 until 2004 [11]. They have developed a risk model in an attempt to predict long-time survival. Their score is based on the factors extrahepatic disease (EHD), major hepatectomy, incomplete (R2) resection, patient age, tumor histology and disease-free interval [11]

Read more

Summary

Introduction

The indication for hepatic resection (HR) in patients suffering from liver metastases (LM) other than colorectal and neuroendocrine tumors is one focus of current multidisciplinary, oncologic considerations. In CRC, large studies elucidated a survival benefit after liver resection for hepatic metastases with a 5-year overall survival of up to 74% [3]. Current evidence shows a benefit for resection of hepatic metastases in CRC independent of number or size, as long as complete tumor clearance can be accomplished [4]. Surgical treatment of metastases from neuroendocrine tumors (NET) has emerged over recent years [5, 6]. In contrast to CRC, cytoreductive surgery for symptomatic hormone-active metastases has become an accepted treatment for NET [7,8,9]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call